Calidi Biotherapeutics Inc (NASDAQ:CLDI) shares are trading lower by 59% to $0.25 during Tuesday’s session after the company announced the pricing of a $6.1 million public offering.
The offering includes various types of warrants with different exercise prices and expiration dates. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.
The offering is expected to close around April 18, pending customary closing conditions, with Ladenburg Thalmann & Co. Inc. serving as the sole placement agent.
See Also: High-Interest Rates Could Cause ‘More Things To Break’ In US Economy By 2025, Warns Strategist
How To Buy CLDI Stock
By now you're likely curious about how to participate in the market for Calidi Biotherapeutics – be it to purchase shares, or even attempt to bet against the company.
In the the case of Calidi Biotherapeutics, which is trading at $0.28 as of publishing time, $100 would buy you 357.14 shares of stock.
According to data from Benzinga Pro, CLDI has a 52-week high of $5.00 and a 52-week low of $0.25.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
